RecruitingPhase 3NCT06994845
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
Studying IgA Nephropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- iptacopan(drug)
- Enrollment
- 31 enrolled
- Eligibility
- 2-18 years · All sexes
- Timeline
- 2025 – 2030
Study locations (14)
- Childrens Hospital Colorado, Aurora, Colorado, United States
- University of Florida Shands Division, Gainesville, Florida, United States
- Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Prim Childrens Hosp Inv Pharm, Salt Lake City, Utah, United States
- Novartis Investigative Site, Nedlands, Western Australia, Australia
- Novartis Investigative Site, Hangzhou, Zhejiang, China
- Novartis Investigative Site, Beijing, China
- Novartis Investigative Site, Beersheba, Israel
- Novartis Investigative Site, Haifa, Israel
- Novartis Investigative Site, Jerusalem, Israel
- Novartis Investigative Site, Petah Tikva, Israel
- Novartis Investigative Site, Kurume, Fukuoka, Japan
- Novartis Investigative Site, Ohtsu, Shiga, Japan
- Novartis Investigative Site, Fuchū, Tokyo, Japan
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06994845 on ClinicalTrials.govOther trials for IgA Nephropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07182227PS-002 for the Treatment of IgA Nephropathy in AdultsPurespring Therapeutics Limited
- RECRUITINGPHASE3NCT07390123Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANHaisco Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE2NCT07305974A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA NephropathyRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
- RECRUITINGPHASE4NCT07030894Nefecon and Ambrisentan in IgA NephropathyThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06989359Phase 2 Study of ADX-038 in Complement-Mediated Kidney DiseaseADARx Pharmaceuticals, Inc.
- RECRUITINGPHASE1NCT07054684Study of BHV-1400 in IgA NephropathyBiohaven Therapeutics Ltd.
- ENROLLING BY INVITATIONEARLY PHASE1NCT07135219A Study of Cizutamig in Patients With Immunoglobulin A NephropathyPeking University First Hospital
- RECRUITINGPHASE3NCT06963827A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney ConditionTakeda